Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Wilson HTM Companies Conference (June 2014)
9 slides from Mayne Pharma's conference presentation, Jun 3, 2014
Slide 1: Mayne Pharma Group Limited Company Presentation
For personal use only Mayne Pharma Group Limited Company Presentation Wilson HTM Companies Conference 3 June 2014
Slide 2: Mayne Pharma overview
Mayne Pharma overview 1H 2014 Sales analysis For personal use only ● A specialty pharmaceutical By business segment company with an increasingly 10% US Products diversified portfolio of products, 20% 39% MP Global pipeline, technologies and footprint A$70m Metrics Contract Services ● Fully integrate
Slide 3: Mayne Pharma business segments
Mayne Pharma business segments For personal use only Mayne Pharma Mayne Pharma Metrics US Products Australia Global Contract Services Overview Manufactures, markets Manufactures Manufactures, markets Provides contract & distributes branded pharmaceuticals for 3rd & distributes branded pharma
Slide 4: Mayne Pharma's international footprint
Mayne Pharma’s international footprint For personal use only Warehouse R&D and manufacturing facility 2,000m2 commercial and 14.6 hectare facility at Greenville, North distribution facility in Carolina has 9,200m2 of manufacturing Montgomery, Alabama space. FDA inspected and cGMP compliant. Annual p
Slide 5: Operating facilities
Operating facilities Facility location Greenville, NC, USA Salisbury, Australia Montgomery, AL, USA For personal use only Location Inspections FDA, MHRA inspected and cGMP compliant FDA, TGA, MHRA inspected and cGMP FDA inspected and cGMP compliant Last FDA inspection May 2014 compliant Last FDA ins
Slide 6: Key US on-market product portfolio
Key US on-market product portfolio Therapeutic For personal use only Type area Product Form ● PAIN ● ESGIC™ ● IR Tablet, IR capsule ● ZEBUTAL™ ● IR Capsule ● LORCET™ ● IR Tablet Branded ● DERMATOLOGY ● Doryx™ (under license to Actavis) ● DR Tablet ● PAIN ● Oxycodone HCl ● IR Tablet, IR Capsule ● Oxy
Slide 7: Growing pipeline in various stages of development
Growing pipeline in various stages of development For personal use only ● R&D spend increased significantly over last 2 years to R&D spend (A$m) build US generic product portfolio $15 ● Since 2012, R&D as a % of sales increased from 5% to $10 10.9 10.8 15% $5 2.5 ● Team of 60 professionals in R&D wi
Slide 8: Contract services, manufacturing and license partners
Contract services, manufacturing and license partners For personal use only ● Vertically integrated model offering analytical Large and diversified customer base services, formulation and commercial manufacturing ● Services over 100 customers in the pharmaceutical and biotechnology sectors, with app
Slide 9: Future catalysts for value
Future catalysts for value For personal use only Growth strategy Strategic acquisitions, US retail generics Doxycycline franchise Itraconazole licensing and partnership maximisation optimisation commercialisation arrangements ● Approval and launch ● Build doxycycline ● Launch Lozanoc™ in ● Execution
Mayne Pharma Group — Wilson HTM Companies Conference (June 2014) on 6ix